Atara Biotherapeutics (NASDAQ:ATRA) Coverage Initiated at Rodman & Renshaw

Stock analysts at Rodman & Renshaw started coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) in a research note issued to investors on Friday,Benzinga reports. The firm set a "buy" rating and a $25.00 price target on the biotechnology company's stock. Rodman & Renshaw's price objective points to a potential upside of 119.30% from the stock's current price.

A number of other equities analysts have also recently issued reports on ATRA. Canaccord Genuity Group increased their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. TD Cowen raised shares of Atara Biotherapeutics to a "strong-buy" rating in a research note on Friday, November 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $18.75.

Atara Biotherapeutics Price Performance

Shares of ATRA traded up $1.47 during trading hours on Friday, hitting $11.40. 152,253 shares of the stock were exchanged, compared to its average volume of 104,916. Atara Biotherapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The business has a 50-day moving average of $10.73 and a 200-day moving average of $9.63. The firm has a market capitalization of $65.66 million, a P/E ratio of -0.44 and a beta of 0.55.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts' consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the previous year, the business posted ($16.50) earnings per share. As a group, analysts forecast that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company's stock valued at $380,000 after purchasing an additional 4,043 shares in the last quarter. State Street Corp raised its position in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company's stock valued at $182,000 after buying an additional 7,680 shares during the last quarter. Vestal Point Capital LP boosted its holdings in Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company's stock worth $1,014,000 after acquiring an additional 12,677 shares during the last quarter. FMR LLC boosted its holdings in Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock worth $204,000 after acquiring an additional 7,381 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth $79,000. Institutional investors and hedge funds own 70.90% of the company's stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.